To Be 17 Again - Anti-Interleukin-17 Treatment for Psoriasis

被引：44
|
作者：
Waisman, Ari [1 ]
机构：
[1] Johannes Gutenberg Univ Mainz, Inst Mol Med, Univ Med Ctr, Mainz, Germany
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2012年 / 366卷 / 13期
关键词：
IL-17 CYTOKINE FAMILY; SKIN INFLAMMATION; HOST-DEFENSE; T-CELL; MICE; INTERLEUKIN-22; REQUIREMENT; DISEASES; IL-22;
D O I：
10.1056/NEJMe1201071
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1251 / 1252
页数：2
相关论文
共 50 条
  • [41] Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
    Fargnoli, Maria Concetta
    CASE REPORTS IN DERMATOLOGY, 2019, 11 : 1 - 3
  • [42] Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis
    Genovese, Mark C.
    Mease, Philip J.
    Greenwald, Maria
    Ritchlin, Christopher T.
    Beaulieu, Andre
    Deodhar, Atul A.
    Newmark, Richard
    Feng, JingYuan
    Erondu, Ngozi
    Nirula, Ajay
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [43] Association of genetic polymorphism of interleukin-17A & interleukin-17F with susceptibility of psoriasis
    Kaur, Rajinder
    Rawat, Arun Kumar
    Kumar, Sunil
    Aadil, Wani
    Alditar, Tahseena
    Narang, Tarun
    Chopra, Dimple
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2018, 148 (04) : 422 - 426
  • [44] Interleukin-17 as a Therapeutic Target in Psoriasis
    Torres, Tiago
    Filipe, Paulo
    ACTA MEDICA PORTUGUESA, 2014, 27 (02): : 252 - 258
  • [45] Significance of Anti-Interleukin-17 Antibodies to Airway Inflammation in Cigarette Smoke-Induced COPD in Mice.
    Shen, N.
    He, B.
    Wang, J.
    Wang, Y. Z.
    Zhao, M. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [46] Pharmacokinetics and Immunogenicity Investigation of a Human Anti-Interleukin-17 Monoclonal Antibody in Non-Naive Cynomolgus Monkeys
    Han, Chao
    Gunn, George R.
    Marini, Joseph C.
    Shankar, Gopi
    Hsu, Helen Han
    Davis, Hugh M.
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (05) : 762 - 770
  • [47] Psoriasis: rationale for targeting interleukin-17
    Girolomoni, G.
    Mrowietz, U.
    Paul, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (04) : 717 - 724
  • [48] Interleukin-17 in skin: psoriasis and yonder
    Puig, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (05) : 859 - 860
  • [49] Psoriasis Interleukin-17A as a therapeutic Target
    Lichert, Frank
    AKTUELLE DERMATOLOGIE, 2014, 40 (12) : 482 - 482
  • [50] Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis
    Graier, T.
    Salmhofer, W.
    Jonak, C.
    Weger, W.
    Koelli, C.
    Gruber, B.
    Sator, P. G.
    Prillinger, K.
    Mlynek, A.
    Schuetz-Bergmayr, M.
    Richter, L.
    Ratzinger, G.
    Painsi, C.
    Selhofer, S.
    Haering, N.
    Wippel-Slupetzky, K.
    Skvara, H.
    Trattner, H.
    Tanew, A.
    Inzinger, M.
    Tatarski, R.
    Bangert, C.
    Ellersdorfer, C.
    Lichem, R.
    Gruber-Wackernagel, A.
    Hofer, A.
    Legat, F.
    Schmiedberger, E.
    Strohal, R.
    Lange-Asschenfeldt, B.
    Schmuth, M.
    Vujic, I
    Hoetzenecker, W.
    Trautinger, F.
    Saxinger, W.
    Muellegger, R.
    Quehenberger, F.
    Wolf, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (06) : 1094 - 1105
12345